Compare ANIK & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIK | OVID |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.8M | 118.9M |
| IPO Year | 1993 | 2017 |
| Metric | ANIK | OVID |
|---|---|---|
| Price | $9.54 | $1.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $16.00 | $3.50 |
| AVG Volume (30 Days) | 154.0K | ★ 1.6M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $112,806,000.00 | $6,610,000.00 |
| Revenue This Year | N/A | $1,077.56 |
| Revenue Next Year | $4.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 30.55 | ★ 945.89 |
| 52 Week Low | $7.87 | $0.24 |
| 52 Week High | $18.37 | $2.01 |
| Indicator | ANIK | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 49.43 | 49.76 |
| Support Level | $9.31 | $1.59 |
| Resistance Level | $9.85 | $1.87 |
| Average True Range (ATR) | 0.20 | 0.11 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 43.12 | 20.97 |
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.